



15 June 2020

Company Announcements Office
Australian Securities Exchange
Exchange Centre
20 Bridge Street
Sydney, NSW 2000

Dear Sir/Madam

MEDLAB COMPLETES SUCCESSFUL \$5.4M PLACEMENT

Medlab Clinical Limited (the **Company**) (ASX: MDC) is pleased to announce that the Company has received firm commitments from new and existing institutional and sophisticated investors and raised AUD\$5.40m (before costs) through the placement of 35,984,020 fully paid ordinary shares (**Shares**) at an issue price of \$0.15 per Share (**Placement**).

The Placement was well supported by existing and new institutional and sophisticated shareholders. Acova Capital and Morgans Corporate Limited acted as Joint Lead Managers to the Placement.

The Placement has been undertaken pursuant to ASX Class Waiver Decision (Temporary Extra Placement Capacity) dated 23 April 2020 (**ASX Class Waiver**) and is within the prescribed 25% limit under the Class Waiver Decision. This means that the Placement is not subject to shareholder approval. All Shares issued pursuant to the Placement will rank equally with existing ordinary shares of the Company.

It is anticipated that settlement of the Placement will occur on Thursday 18 June 2020 with the new Shares being allotted Friday 19 June 2020.

In addition to the Placement, in recognition of the Company's existing shareholders, eligible shareholders will have the opportunity to participate in a Share Purchase Plan (SPP) at the same issue price as the Placement of A\$0.15 per Share (Offer Price). The Offer Price represents a 26.8% discount to last close of A\$0.205 on 10 June 2020.

The Company intends to raise up to A\$4.00m under the SPP which is not underwritten.

Under the SPP, the Company will offer all eligible shareholders with a registered address in Australia the opportunity to apply for up to \$30,000 Shares without incurring brokerage, commissions, stamp duty or other transaction costs of new Shares (subject to any pro-rata scale back). The SPP is being offered in reliance of the ASX Class Waiver. The Company reserves the right to scale back applications in its sole discretion. If applications are scaled back, excess funds will be returned to applicants without interest.

Participation in the SPP is optional and is open to Eligible Shareholders who, as at Friday, 12 June 2020 (**Record Date**), were registered as holders of ordinary shares in Medlab. As agreed with the ASX, the Directors and executives of the Company will not be participating in the Placement or the SPP.

The indicative timetable for the SPP is set out below:

Events	Dates
Record Date (being the business day prior to Medlab's announcement of the Plan)	5pm (Sydney time), Friday, 12 June 2020
Medlab announcement of Plan	Monday, 15 June 2020
Opening Date, dispatch of SPP Plan	9am (Sydney time) Wednesday, 17 June 2020
Closing Date	5pm (Sydney time) Friday, 3 July 2020
Issue Date	Tuesday, 7 July 2020
Date on which Shares issued under the Offer are expected to commence trading on the ASX	Wednesday, 8 July 2020
Despatch of holding statements in respect of Shares issued under the Offer	Thursday, 9 July 2020

Note: Medlab reserves the right to vary the dates and times set out above subject to the Corporations Act and other applicable laws.

The proceeds of the Placement and SPP will be used as follows:

- Ensure path of NanaBis™ to Phase 3 trials submission are uninterrupted – this is a key valuation milestone
- Funding to bridge multiple research catalysts over next 12 months
- Working capital for VMS inventory to maintain sales and promote new sales channel
- Working capital for NanaBis™ inventory for growing sales and international markets / and NanoCBD launch
- Ensuring adequate funding to cover any potential COVID related regulatory delay

Medlab CEO, Sean Hall said “the support shown for the Placement has been extremely pleasing and appreciated. These funds help the Company to ensure the path of NanaBis™ to Phase 3 trials submissions are uninterrupted. I would like to thank the ongoing support from existing shareholders, and we welcome a number of new institutional and sophisticated shareholders to Medlab. I would like to take this opportunity to thank Morgans Corporate Limited and Acova Capital for completing the successful Placement.”

For and behalf of the Board.



Dr Sean Hall
Managing Director